Autolus Therapeutics Q3 2023 Earnings Report $2.01 -0.06 (-2.90%) As of 03/7/2025 04:00 PM Eastern Earnings HistoryForecast Autolus Therapeutics EPS ResultsActual EPS-$0.26Consensus EPS -$0.24Beat/MissMissed by -$0.02One Year Ago EPSN/AAutolus Therapeutics Revenue ResultsActual Revenue$0.41 millionExpected Revenue$2.00 millionBeat/MissMissed by -$1.59 millionYoY Revenue GrowthN/AAutolus Therapeutics Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AAUTL Upcoming EarningsAutolus Therapeutics will be holding an earnings conference call on Thursday, March 20 at 8:30 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesSlide DeckPress ReleaseAUTL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Autolus Therapeutics Earnings HeadlinesEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for WeekMarch 7 at 11:31 AM | msn.comAutolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025March 6, 2025 | globenewswire.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.March 10, 2025 | Chaikin Analytics (Ad)Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?March 6, 2025 | insidermonkey.comAutolus Therapeutics to Participate in Upcoming Investor ConferencesMarch 5, 2025 | globenewswire.comAutolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell TherapyMarch 4, 2025 | seekingalpha.comSee More Autolus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Autolus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autolus Therapeutics and other key companies, straight to your email. Email Address About Autolus TherapeuticsAutolus Therapeutics (NASDAQ:AUTL), a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.View Autolus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
